

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040.70006US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
			APPLICANT: McCluskie et al.	
			GROUP ART UNIT: 1633	EXAMINER: Quang Nguyen
OCT 02 2007				
1 of 5				

### U.S. PATENT DOCUMENTS

Examiner's Initials # TRADEMARK No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
	Number	Kind Code		
	6,221,882	B1	Macfarlane	04-24-2001
	6,399,630	B1	Macfarlane	06-04-2002
	6,479,504	B1	Macfarlane et al.	11-12-2002
	6,521,637	B2	Macfarlane	02-18-2003
	6,943,240	B2	Bauer et al.	09-13-2005
	6,949,520	B1	Hartmann et al.	09-27-2005
	7,001,890	B1	Wagner et al.	02-21-2006
	7,223,741	B2	Krieg	05-29-2007
	2002-0156033	A1	Bratzler et al.	10-24-2002
	2003-0232856	A1	Macfarlane	12-18-2003
	2004-0067902	A9	Bratzler et al.	04-08-2004
	2004-0198680	A1	Krieg	10-07-2004
	2004-0229835	A1	Krieg et al.	11-18-2004
	2004-0234512	A1	Wagner et al.	11-25-2004
	2004-0235770	A1	Davis et al.	11-25-2004
	2004-0235774	A1	Bratzler et al.	11-25-2004
	2004-0235777	A1	Wagner et al.	11-25-2004
	2004-0235778	A1	Wagner et al.	11-25-2004
	2004-0266719	A1	McCluskie et al.	12-30-2004
	2005-0004061	A1	Krieg et al.	01-06-2005
	2005-0004062	A1	Krieg et al.	01-06-2005
	2005-0009774	A1	Krieg et al.	01-13-2005
	2005-0032734	A1	Davis et al.	02-10-2005
	2005-0032736	A1	Krieg et al.	02-10-2005
	2005-0037403	A1	Krieg et al.	02-17-2005
	2005-0037985	A1	Krieg et al.	02-17-2005
	2005-0043529	A1	Davis et al.	02-24-2005
	2005-0049215	A1	Krieg et al.	03-03-2005
	2005-0049216	A1	Krieg et al.	03-03-2005
	2005-0054601	A1	Wagner et al.	03-10-2005
	2005-0054602	A1	Krieg et al.	03-10-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040.70006US00
				FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
				APPLICANT: McCluskie et al.	
				GROUP ART UNIT: 1633	EXAMINER: Quang Nguyen
Sheet	2	of	5		

		2005-0059619	A1	Krieg et al.	03-17-2005
		2005-0059625	A1	Krieg et al.	03-17-2005
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0075302	A1	Hutcherson et al.	04-07-2005
		2005-0100983	A1	Bauer et al.	05-12-2005
		2005-0101554	A1	Krieg et al.	05-12-2005
		2005-0101557	A1	Krieg et al.	05-12-2005
		2005-0119273	A1	Lipford et al.	06-02-2005
		2005-0123523	A1	Krieg et al.	06-09-2005
		2005-0130911	A1	Uhlmann et al.	06-16-2005
		2005-0148537	A1	Krieg et al.	07-07-2005
		2005-0169888	A1	Hartman et al.	08-04-2005
		2005-0171047	A1	Krieg et al.	08-04-2005
		2005-0181422	A1	Bauer et al.	08-18-2005
		2005-0182017	A1	Krieg	08-18-2005
		2005-0197314	A1	Krieg et al.	09-08-2005
		2005-0215501	A1	Lipford et al.	09-29-2005
		2005-0233995	A1	Krieg et al.	10-20-2005
		2005-0233999	A1	Krieg et al.	10-20-2005
		2005-0239732	A1	Krieg et al.	10-27-2005
		2005-0239733	A1	Jurk et al.	10-27-2005
		2005-0239734	A1	Uhlmann et al.	10-27-2005
		2005-0239736	A1	Krieg et al.	10-27-2005
		2005-0244379	A1	Krieg et al.	11-03-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2005-0250726	A1	Krieg et al.	11-10-2005
		2005-0256073	A1	Lipford et al.	11-17-2005
		2005-0267064	A1	Krieg et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2005-0277609	A1	Krieg et al.	12-15-2005
		2006-0003955	A1	Krieg et al.	01-05-2006
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040.70006US00
				FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
				APPLICANT: McCluskie et al.	
				GROUP ART UNIT: 1633	EXAMINER: Quang Nguyen
Sheet	3	of	5		

		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875	A1	Krieg et al.	06-29-2006
		2006-0154890	A1	Bratzler et al.	07-13-2006
		2006-0172966	A1	Lipford et al.	08-03-2006
		2006-0188913	A1	Krieg et al.	08-24-2006
		2006-0211639	A1	Bratzler et al.	09-21-2006
		2006-0211644	A1	Krieg et al.	09-21-2006
		2006-0229271	A1	Krieg et al.	10-12-2006
		2006-0241076	A1	Uhlmann et al.	10-26-2006
		2006-0246035	A1	Ahluwalia et al.	11-02-2006
		2006-0286070	A1	Hartmann et al.	12-21-2006
		2006-0287263	A1	Davis et al.	12-21-2006
		2007-0009482	A1	Krieg et al.	01-11-2007
		2007-0010470	A1	Krieg et al.	01-11-2007
		2007-0037767	A1	Bratzler et al.	02-15-2007
		2007-0065467	A1	Krieg et al.	03-22-2007
		2007-0066553	A1	Krieg et al.	03-22-2007
		2007-0066554	A1	Krieg et al.	03-22-2007
		2007-0078104	A1	Krieg et al.	04-05-2007
		2007-0129320	A9	Davis et al.	06-07-2007
		2007-0142315	A1	Forsbach et al.	06-21-2007
		2007-0184465	A1	Wagner et al.	08-09-2007
		2007-0202128	A1	Krieg et al.	08-30-2007

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
		WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
		WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040.70006US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
				APPLICANT: McCluskie et al.	
Sheet	4	of	5	GROUP ART UNIT: 1633	EXAMINER: Quang Nguyen

		WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
		WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	
		WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
		WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
		WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov;24(6):693-701.	
		DAVIS et al., DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med. 1999 Mar;66(2):84-90.	
		DE LA ROSA et al., Microbiological quality of pharmaceutical raw materials. Pharm Acta Helv. 1995 Sep;70(3):227-32.	
		DIWAN et al., Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target. 2003;11(8-10):495-507.	
		GAO et al., Swelling of hydroxypropyl methylcellulose matrix tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release. J Pharm Sci. 1996 Jul;85(7):732-40.	
		GOMBOTZ et al., Protein release from alginate matrices. Adv Drug Deliv Rev. 1998 May 4;31(3):267-285.	
		HORNER et al., Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 1998 Nov 25;190(1):77-82.	
		LI et al., Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine. 2001 Oct 12;20(1-2):148-57.	
		LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.	
		McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1;161(9):4463-6.	
		MUI et al., Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther. 2001 Sep;298(3):1185-92.	
		MUTWIRI et al., Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004 May 31;97(1):1-17.	
		OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040.70006US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
				APPLICANT: McCluskie et al.	
Sheet	5	of	5	GROUP ART UNIT: 1633	EXAMINER: Quang Nguyen

		SCHIJNS. Immunological concepts of vaccine adjuvant activity. <i>Curr Opin Immunol.</i> 2000 Aug;12(4):456-63.	
		SEMPLE et al., Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. <i>J Pharmacol Exp Ther.</i> 2005 Mar;312(3):1020-6.	
		SHAO et al., CpG-containing oligodeoxynucleotide 1826 converts the weak uveitogenic rat interphotoreceptor retinoid-binding protein peptide 1181-1191 into a strong uveitogen. <i>J Immunol.</i> 2003 Nov 1;171(9):4780-5.	
		SUZUKI et al., Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. <i>Cancer Res.</i> 2004 Dec 1;64(23):8754-60.	
		TAFAGHODI et al., Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. <i>Int J Pharm.</i> 2006 Aug 17;319(1-2):37-43.	
		TAM et al., Liposomal encapsulation enhances the activity of immunostimulatory oligonucleotides. <i>Future Lipidology.</i> 2006 Feb; 1(1): 35-46	
		UGOZZOLI et al., Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. <i>Immunology.</i> 1998 Apr;93(4):563-71.	
		VON HUNOLSTEIN et al., Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with <i>Haemophilus influenzae</i> type b conjugate vaccine. <i>Int Immunol.</i> 2000 Mar;12(3):295-303.	
		VON HUNOLSTEIN et al., The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti- <i>Haemophilus influenzae</i> type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. <i>Vaccine.</i> 2001 Apr 30;19(23-24):3058-66.	
		WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. <i>Int Immunol.</i> 2003 Feb;15(2):223-31.	
		WEERATNA et al., TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). <i>Vaccine.</i> 2005 Nov 1;23(45):5263-70.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.